evocalcet
Selected indexed studies
- Development of evocalcet for unmet needs among calcimimetic agents. (Expert Rev Endocrinol Metab, 2020) [PMID:32552012]
- Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. (Ther Apher Dial, 2020) [PMID:31486206]
- Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism. (PLoS One, 2022) [PMID:35176038]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Development of evocalcet for unmet needs among calcimimetic agents. (2020) pubmed
- Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. (2020) pubmed
- Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism. (2022) pubmed
- Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats. (2023) pubmed
- Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism. (2020) pubmed
- Effectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism. (2025) pubmed
- Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients. (2021) pubmed
- Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism. (2022) pubmed
- Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. (2019) pubmed
- Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. (2020) pubmed